Skip to main content
SpringerLink
Log in

Permeability classification of representative fluoroquinolones by a cell culture method

  • Published:
AAPS PharmSci Aims and scope Submit manuscript

Abstract

This study was undertaken to categorize representative fluoroquinolone drug substance permeability based on the methods outlined in the Food and Drug Administration's biopharmaceutic classification system (BCS) Guidance for Industry. The permeability of ciprofloxacin, levofloxacin, lomefloxacin, and ofloxacin was measured in an in vitro Caco-2 assay with previously demonstrated method suitability. The permeability class and efflux potential were ascertained by comparing test drug results with standard compounds (metoprolol, atenolol, labetalol, and rhodamine-123). All 4 quinolones drugs demonstrated concentration-dependent permeability, indicating active drug transport. In comparing absorptive versus secretive in vitro transport, the tested fluoroquinolones were found to be subject to efflux in varying degrees (ciprofloxacin > lomefloxacin > rhodamine 123 > levofloxacin > ofloxacin). Based on comparison to labetalol, the high permeability internal standard, ciprofloxacin was classified as a low permeability drug, whereas lomefloxacin, levofloxacin, and ofloxacin were classified as high permeability drugs. The in vitro permeability results matched human in vivo data based on absolute bioavailabilities. This laboratory exercise demonstrated the applicability of an in vitro permeability method for classifying drugs as outlined in the BCS Guidance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–420.

    Article  CAS  PubMed  Google Scholar 

  2. Center for Drug Evaluation and Research. Food and Drug Administration. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Available at: http://www.fda.gov/cder/guidance/3618fnl.pdf. Accessed August 2000.

  3. Volpe DA, Ciavarella AB, Asafu-Adjaye EB, Ellison CD, Faustino PJ, Yu LX. Method suitability of a Caco-2 cell model for drug permeability classification [abstract]. AAPS Pharm Sci. 2001; 3(S 1). Available at: http://www.aapspharmaceutica.com/search/abstract_view. asp?id=385&ct=01Abstracts.

  4. Owens RC, Ambrose PG. Clinical use of the fluoroquinolones. Med Clin North Am. 2000;84:1447–1469.

    Article  CAS  PubMed  Google Scholar 

  5. Hooper DC. Mode of action of fluoroquinolones. Drugs. 1999;58(suppl 2):6–10.

    Article  CAS  PubMed  Google Scholar 

  6. Pickerill KE, Paladino JA, Schentag JJ. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy. 2000;20:417–428.

    Article  CAS  PubMed  Google Scholar 

  7. Lode H, Hoffken G, Boeckk M, Deppermann N, Bomer K, Koeppe P. Quinolone pharmacokinetics and metabolism. J Antimicrob Chemother. 1990;26(suppl B):41–49.

    Article  CAS  PubMed  Google Scholar 

  8. Cipro® (ciprofloxacin hydrochloride tablets) [product information]. West Haven, CT: Bayer Corporation; 2000.

  9. Levaquin® (levofloxacin tablets/injection) [product information]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc; 2000.

  10. Maxaquin® (lomefloxacin hydrochloride tablets) [product information]. Buffalo Grove, IL: Unimed Pharmaceuticals; 1999.

  11. Floxin® (ofloxacin tablets) [product information]. Raritan, NJ: Ortho-McNeil Pharmaceutical Inc; 1998.

  12. Bergan T. Pharmacokinetics of fluorinated quinolones. In: Andriole VT, ed. The Quinolones. London, UK: Academic Press; 1988: 119–152.

    Chapter  Google Scholar 

  13. Cavet ME, West M, Simmons NL. Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol. 1997;121:1567–1578.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Griffiths NM, Hirst BH, Simmons NL. Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway? J Pharmacol Exp Ther. 1994;269:496–502.

    CAS  PubMed  Google Scholar 

  15. Griffiths NM, Hirst BH, Simmons NL. Active secretion of the fluoroquinolone ciprofloxacin by human intestinal epithelial Caco-2 cell layers. Br J Pharmacol. 1993;108:575–576.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Yamaguchi H, Yano I, Saito H, Inui K. Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2. Eur J Pharmacol. 2001;431:297–303.

    Article  CAS  PubMed  Google Scholar 

  17. Yamaguchi H, Yano I, Hashimoto Y, Inui KI. Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2. J Pharmacol Exp Ther. 2000;295:360–366.

    CAS  PubMed  Google Scholar 

  18. Awadallah B, Wahl MA. Transport of ofloxacin enantiomers in the Caco-2-TC7 cell line [abstract]. AAPS Pharm Sci. 2002; 4(S1). Abstract W5049. Available at: http://www.aapspharmsci.org.

  19. Rodriguez-Ibáñez M, Nalda-Molina R, Montala-Montero M, Bermejo MV, Merino V, Garrigues TM. Transintestinal secretion of ciprofloxacin, grepafloxacin and sparafloxacin: in vitro and in situ inhibition studies. Eur J Pharm Biopharm. 2003;55:241–246.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Product Quality Research, Center for Drug Evaluation and Research, Food and Drug Administration, Life Sciences Building 64, HFD-940, 10903 New Hampshire Ave., 20993, Silver Spring, MD

    Donna A. Volpe

Authors
  1. Donna A. Volpe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donna A. Volpe.

Additional information

Published: April 5, 2004

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Volpe, D.A. Permeability classification of representative fluoroquinolones by a cell culture method. AAPS J 6, 13 (2004). https://doi.org/10.1208/ps060213

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/ps060213

KeyWords

Search

Navigation